AIM ImmunoTech Inc. (AMEX:AIM) demonstrates remarkable capital efficiency with a Return on Invested Capital (ROIC) of 443.97%, significantly surpassing its peers in the biotechnology sector.The company's ROIC far exceeds its Weighted Average Cost of Capital (WACC), with a ratio of 76.10, indicating efficient use of capital to generate profits.In contrast, peers like Aytu BioPharma, Inc. (AYTU), iBio, Inc. (IBIO), and others show negative ROIC to WACC ratios, highlighting inefficiencies in capital utilizatio ...